Results 41 to 50 of about 65,249 (309)

Drug-Resistant Tuberculosis--Current Dilemmas, Unanswered Questions, Challenges and Priority Needs [PDF]

, 2012
Tuberculosis was declared a global emergency by the World Health Organization (WHO) in 1993. Following the declaration and the promotion in 1995 of directly observed treatment short course (DOTS), a cost-effective strategy to contain the tuberculosis ...
Abubakar, Ibrahim, Atun, Rifat, Chakaya, Jeremiah, Cox, Helen, Ditiu, Lucica, Ford, Nathan, Grobusch, Martin, Hoelscher, Michael, Lawn, Stephen D., Maeurer, Markus, Marais, Ben, Mchugh, Timothy D., McNerney, Ruth, Memish, Ziad, Migliori, Giovanni-Battista, Mwaba, Peter, O'Grady, Justin, Pletschette, Michel, Ramsay, Andrew, Raviglione, Mario, Schito, Marco, Squire, S. Bertel, Swaminathan, Soumya, Zumla, Alimuddin   +23 more
core   +1 more source

Current State of Compassionate Phage Therapy

Viruses, 2019
There is a current unmet medical need for the treatment of antibiotic-resistant infections, and in the absence of approved alternatives, some clinicians are turning to empirical ones, such as phage therapy, for compassionate treatment.
Shawna McCallin, Jessica C. Sacher, Jan Zheng, Benjamin K. Chan   +3 more
doaj   +1 more source

Long-Term Survival and Immune Response Dynamics in Melanoma Patients Undergoing TAPCells-Based Vaccination Therapy

Vaccines
Cancer vaccines present a promising avenue for treating immune checkpoint blockers (ICBs)-refractory patients, fostering immune responses to modulate the tumor microenvironment. We revisit a phase I/II trial using Tumor Antigen-Presenting Cells (TAPCells)
Andrés Tittarelli, Cristian Pereda, María A. Gleisner, Mercedes N. López, Iván Flores, Fabián Tempio, Alvaro Lladser, Adnane Achour, Fermín E. González, Claudia Durán-Aniotz, Juan P. Miranda, Milton Larrondo, Flavio Salazar-Onfray   +12 more
doaj   +1 more source

Patients' Attitudes to Unproven Therapies in Treating COVID-19 Merit Evaluation

The Innovation, 2020
Since the outbreak of COVID-19, many randomized controlled trials have been launched to test the efficacy of promising treatments. These trials will offer great promise for future treatment.
Hong-tian Li, Zhi-hao Cheng, Yong-ying Huang, Xi-lin Lv, Yu-bo Zhou, Erdan Dong, Jian-meng Liu   +6 more
doaj   +1 more source

Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.

PLoS ONE, 2021
The U.S. Food and Drug Administration (FDA) allows patients with serious illnesses to access investigational drugs for "compassionate use" outside of clinical trials through expanded access (EA) Programs.
Jeremiah Stout, Cambray Smith, Jan Buckner, Alex A Adjei, Mark Wentworth, Jon C Tilburt, Zubin Master   +6 more
doaj   +1 more source

Phage Therapy: Towards a Successful Clinical Trial

Antibiotics, 2020
While phage therapy carried out as compassionate use (experimental therapy) has recently flourished, providing numerous case reports of supposedly healed patients, clinical trials aiming to formally prove their value in accord with current regulatory ...
Andrzej Górski, Jan Borysowski, Ryszard Międzybrodzki   +2 more
doaj   +1 more source

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial [PDF]

Leukemia, 2001
To confirm the efficacy of recombinant urate oxidase (rasburicase) and to establish its safety profile, we reviewed the data on 173 children and 72 adults with malignancy who were treated with this new uricolytic agent in a compassionate-use trial. Rasburicase (0.20 mg/kg) was administered intravenously daily for 1 to 7 days and could be given every 12
C H, Pui, S, Jeha, D, Irwin, B, Camitta
openaire   +2 more sources

Making Compassionate Use More Useful: Using real-world data, real-world evidence and digital twins to supplement or supplant randomized controlled trials.

Biocomputing 2021, 2020
The coronavirus pandemic has placed renewed focus on expanded access (EA) programs to provide compassionate use exceptions to the waves of patients seeking medical care in treating the novel disease. While commendable, justifiable, and compassionate, EA programs are not designed to collect the necessary vital clinical data that can be later used in the
openaire   +2 more sources

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul, Jatuporn Sujjitjoon, Pa‐thai Yenchitsomanus, Kridtin Jarutatsanangkoon, Ng Wei Loon, Kleebsabai Sanpakit, Jassada Buaboonnam, Chayamon Takpradit, Pornpimon Yuti, Nunghathai Sawasdee, Piriya Luangwattananun, Siripakorn Sangkitporn, Arnan Limmahachai, La‐ongsri Atchaneeyasakul   +13 more
wiley   +1 more source

Pediatric Oncology Nursing Competencies in Latin America and the Caribbean: A Scoping Review to Inform Practice, Education, and Research

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Nurses are central to cancer care for children and adolescents, yet no comprehensive synthesis has defined essential core competencies for pediatric oncology nursing (PON) practice internationally, particularly in Latin America and the Caribbean (LAC).
Luís Carlos Lopes‐Júnior, Edmara Bazoni Soares Maia, Soad Fuentes‐Alabí, Courtney E. Sullivan, Monnie Abraham, Mauricio Maza, Liliana Vásquez Ponce, Regina Aparecida Garcia Lima   +7 more
wiley   +1 more source